<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4041">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642950</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-26-1</org_study_id>
    <nct_id>NCT04642950</nct_id>
  </id_info>
  <brief_title>A Phase II/III Study of Sargramostim</brief_title>
  <official_title>A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study&#xD;
      to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days,&#xD;
      in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-rank improvement on a 7-point ordinal scale</measure>
    <time_frame>Period until Day 28 (including the case after discharge).</time_frame>
    <description>Number of days to achieve at least 2-rank improvement on a 7-point ordinal scale from baseline until Day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in alveolar-arterial oxygen partial pressure gradient (A-aDO)</measure>
    <time_frame>Period until Day 28 (including the case after discharge).</time_frame>
    <description>Changes in alveolar-arterial oxygen partial pressure gradient (A-aDO) on Day 5 and Day 10 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until discharge from baseline</measure>
    <time_frame>Period until Day 28 (including the case after discharge).</time_frame>
    <description>Number of days until discharge from baseline (days of shifting to Category 7 on a 7-point ordinal scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose category has shifted to Category 1 or 2</measure>
    <time_frame>Period until Day 28 (including the case after discharge).</time_frame>
    <description>Proportion of subjects whose category has shifted to Category 1 or 2 on a 7-point ordinal scale from baseline until Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>NPC-26</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sargramostim (125 μg) will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP-26 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiological saline will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.</description>
    <arm_group_label>NPC-26</arm_group_label>
    <other_name>Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.</description>
    <arm_group_label>NP-26 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Japanese male or female subjects who have been confirmed to meet all the following&#xD;
        criteria.&#xD;
&#xD;
          1. Hospitalized patients under treatment who were severe acute respiratory syndrome&#xD;
             coronavirus 2 [SARS-CoV-2] positive by polymerase chain reaction (PCR) test.&#xD;
&#xD;
          2. Patients with clinically diagnosed pneumonia and a percutaneous oxygen saturation&#xD;
             [SpO2] of 93% or less on breathing of room air at bed rest.&#xD;
&#xD;
          3. Patients for whom written informed consent has been obtained from those themselves or&#xD;
             the legally acceptable representatives.&#xD;
&#xD;
          4. Patients aged 20 years or older and younger than 80 years at the time of obtaining&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded. Unless otherwise stated,&#xD;
        the following criteria refer to those at the time of screening.&#xD;
&#xD;
          1. Patients who have been participating in other intervention studies, such as studies on&#xD;
             unapproved pharmacotherapy, within 90 days prior to screening.&#xD;
&#xD;
          2. Patients who have experienced off-label use of approved drugs (including those for&#xD;
             COVID-19 treatment other than steroids as standard treatment) within 7 days prior to&#xD;
             screening.&#xD;
&#xD;
          3. Patients who are not expected to survive longer than 24 hours after commencement of&#xD;
             study drug administration.&#xD;
&#xD;
          4. Patients who are using invasive ventilator or extracorporeal membrane oxygenation&#xD;
             (ECMO).&#xD;
&#xD;
          5. Patients who have a chronic respiratory disease requiring continuous home oxygen&#xD;
             therapy or ventilator use.&#xD;
&#xD;
          6. Patients with an underlying condition that is considered very unlikely to withdraw&#xD;
             ventilator (e.g., motor neuron disease, Duchenne muscular dystrophy, rapidly&#xD;
             progressive interstitial pulmonary fibrosis).&#xD;
&#xD;
          7. Patients who have a disease including bronchial asthma, lower respiratory tract&#xD;
             infections, and interstitial lung diseases that may affect the assessment of the&#xD;
             clinical study, since before the symptom onset of COVID-19.&#xD;
&#xD;
          8. Patients who have a disease including leukemia and leukocytosis that causes&#xD;
             leukocytosis.&#xD;
&#xD;
          9. Patients who have a chronic kidney disease requiring dialysis.&#xD;
&#xD;
         10. Patients who have severe liver failure (Child Pugh grade C).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Masaki Taniguchi</last_name>
    <phone>+ 81-3-6670-3800</phone>
    <email>taniguchi.masaki@nobelpharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>IUHW Narita Hospital</name>
      <address>
        <city>Narita City</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaki Taniguchi</last_name>
      <phone>+ 81-3-6670-3800</phone>
      <email>taniguchi.masaki@nobelpharma.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Yokohama City</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaki Taniguchi</last_name>
      <phone>+ 81-3-6670-3800</phone>
      <email>taniguchi.masaki@nobelpharma.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Society Saitama Red Cross Hospital</name>
      <address>
        <city>Saitama City</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaki Taniguchi</last_name>
      <phone>+ 81-3-6670-3800</phone>
      <email>taniguchi.masaki@nobelpharma.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's International Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaki Taniguchi</last_name>
      <phone>+ 81-3-6670-3800</phone>
      <email>taniguchi.masaki@nobelpharma.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Medical Center</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaki Taniguchi</last_name>
      <phone>+ 81-3-6670-3800</phone>
      <email>taniguchi.masaki@nobelpharma.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaki Taniguchi</last_name>
      <phone>+ 81-3-6670-3800</phone>
      <email>taniguchi.masaki@nobelpharma.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

